Zai Lab Ltd

ZLAB

NASDAQ. Currency in USD

37.43 +0.43 ( +1.16% )

Real time prices: September 26

Market Cap.
3.66B
Beta (5Y monthly)
1.00
Price/Earnings
-
EPS (TTM)
-5.55
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
458,258
1y Target Est.
191.87
Day's Range
35.89
-
38.71
52 Week's Range
22.51
-
112.16

Historical Summary

Performance
EPS growth
Share Buybacks

About Zai Lab Ltd

Sector
Healthcare
Industry
Biotechnology
Website
https://www.zailaboratory.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
97.91M
Employees
1951
Address
Jinchuang Plaza, Shanghai, China, 201210
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

Latest news

US Stocks Open Higher, Dow Surges 300 Points
US Stocks Open Higher, Dow Surges 300 Points

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points...
By Benzinga - 2 weeks ago

Why Nuwellis Surged Over 121%; Here Are 66 Biggest Movers From Yesterday
Why Nuwellis Surged Over 121%; Here Are 66 Biggest Movers From Yesterday

Gainers Nuwellis, Inc. (NASDAQ: NUWE) shares climbed 121.3% to close at $1.46 on Wednesday after...
By Benzinga - 3 weeks ago

Why Express Is Trading Higher By Over 21%, Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
Why Express Is Trading Higher By Over 21%, Here Are 54 Stocks Moving In Wednesday's Mid-Day Session

Gainers Nuwellis, Inc. (NASDAQ: NUWE) shares jumped 140% to $1.5894 after the company announced new...
By Benzinga - 3 weeks ago

Snap, Meta Platforms, Pinterest And Some Other Big Stocks Moving Higher On Wednesday
Snap, Meta Platforms, Pinterest And Some Other Big Stocks Moving Higher On Wednesday

Barnes & Noble Education, Inc. (NYSE: BNED) gained 16.8% to $2.64 after reporting upbeat quarterly...
By Benzinga - 3 weeks ago

Zai Lab Announces Participation in September Investor Conferences
Zai Lab Announces Participation in September Investor Conferences

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab...
By GlobeNewswire Inc. - 4 weeks ago

Tesla, Twitter And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Tesla, Twitter And Some Other Big Stocks Moving Higher In Today's Pre-Market Session

The Trade Desk, Inc. (NASDAQ: TTD) rose 17.3% to $63.90 in pre-market trading after the...
By Benzinga - 6 weeks ago

Why Earnings Season Could Be Great for Zai Lab (ZLAB)
Why Earnings Season Could Be Great for Zai Lab (ZLAB)

Zai Lab (ZLAB) is seeing favorable earnings estimate revision activity and has a positive Zacks...
By Zacks Investment Research - 7 weeks ago

Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total...
By GlobeNewswire Inc. - 7 weeks ago